Investors Sell Shares of Pfizer (PFE) on Strength (PFE)

Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Friday. $205.87 million flowed into the stock on the tick-up and $336.42 million flowed out of the stock on the tick-down, for a money net flow of $130.55 million out of the stock. Of all equities tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.53 for the day and closed at $34.16

Several equities research analysts recently commented on PFE shares. Jefferies Group set a $38.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. BMO Capital Markets restated a “buy” rating and set a $39.00 target price (up previously from $37.00) on shares of Pfizer in a research report on Thursday, October 19th. Berenberg Bank set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, October 31st. UBS Group set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average target price of $39.45.

The stock has a market cap of $203,620.00, a price-to-earnings ratio of 9.70, a PEG ratio of 1.93 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 earnings per share. equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.98%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

Pfizer declared that its board has authorized a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

In other news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of PFE. HL Financial Services LLC increased its position in shares of Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after acquiring an additional 35,744 shares during the last quarter. Hartford Financial Management Inc. increased its position in shares of Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 835 shares during the last quarter. Cadence Bank NA increased its position in shares of Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 1,428 shares during the last quarter. Majedie Asset Management Ltd increased its position in shares of Pfizer by 7.9% during the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after acquiring an additional 24,531 shares during the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its position in shares of Pfizer by 437.9% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after acquiring an additional 629,361 shares during the last quarter. Institutional investors own 69.87% of the company’s stock.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/02/11/investors-sell-shares-of-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply